JPRN-UMIN000013467已完成2 期
Phase 2 study to evaluate the efficacy and the safety of clarithromycin, lenalidomide and dexamethasone (Personalized BiRd) for patients with relapsed or refractory multiple myeloma - Personalized BiRd for relapsed or refractory multiple myeloma
Yokohama Municipal Citizen's Hospital0 个研究点目标入组 12 人开始时间: 2014年3月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients who have peripheral neuropathy or peripheral neuropathic pain of grade 2 or more. (2)Patients who have had a complication of active double cancer within the past 5 years. (3)HBs antigen positive,HCV antibody positive, HIV antibody positive patients (4) serious mental disorders such as schizophrenia (5) Patients with a clinical picture of pneumonia (interstitial pneumonia) or fibroid lung or an abnormal bilateral interstitial abnormality on chest CT scan regardless of the presence or absence of symptoms (6) Patients with severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection (7)Patients with plasma cell leukemia, cardiac amyloidosis and POEMS syndrome (8)Ptients with thrombosis (9)Women who are or may be pregnant (10)Other patients who are,in the opinion of the caring investigator, unfit for enrollment in the study
研究者
相似试验
进行中（未招募）
不适用
Phase II study to investigate the efficacy and safety of ZK 219477 as first-line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC)Extensive disease (ED) stage small cell lung cancer (SCLC)EUCTR2005-000597-53-DESchering AG
进行中（未招募）
不适用
Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC)on small cell lung cancer (NSCLC) stage IIIB or stage IVEUCTR2005-000586-19-DEBayer Schering Pharma AG
进行中（未招募）
1 期
A phase II study investigating the efficacy and safety of Vvax001, a therapeutic cancer vaccine, in patients with premalignant cervical lesions.EUCTR2019-004050-29-NLniversity Medical Center Groningen18
招募中
2 期
A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia.NL-OMON55191niversitair Medisch Centrum Groningen18
终止
2 期
A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Study to Evaluate The Efficacy and Safety of T89, drug name: Dantonic 'Registered trade mark' in Patients with Chronic Stable Angina PectorisChronic Stable Angina PectorisAnginaCardiovascular - Coronary heart diseaseACTRN12609000044224CNS Pty Ltd70